Evidence map›Paper›PMID 40511257›Full record

ArticleRegenerative therapy2025

Generation of canine induced pluripotent stem cell-derived mesenchymal stem cells: Comparison of differentiation strategies and cell origins.

Masaya Tsukamoto, Chiaki Kawabata, Kohei Shishida, Takumi Yoshida, Kazuto Kimura, Kazuya Edamura, Kikuya Sugiura, Shingo Hatoya

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Regenerative therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Masaya TsukamotoDepartment of Advanced Pathobiology, Graduate School of Veterinary Science, Osaka Metropolitan University, Izumisano, Osaka 598-8531, Japan.
Chiaki KawabataDepartment of Advanced Pathobiology, Graduate School of Veterinary Science, Osaka Metropolitan University, Izumisano, Osaka 598-8531, Japan.
Kohei ShishidaDepartment of Advanced Pathobiology, Graduate School of Veterinary Science, Osaka Metropolitan University, Izumisano, Osaka 598-8531, Japan.
Takumi YoshidaDepartment of Advanced Pathobiology, Graduate School of Veterinary Science, Osaka Metropolitan University, Izumisano, Osaka 598-8531, Japan.
Kazuto KimuraDepartment of Advanced Pathobiology, Graduate School of Veterinary Science, Osaka Metropolitan University, Izumisano, Osaka 598-8531, Japan.
Kazuya EdamuraLaboratory of Veterinary Surgery, Department of Veterinary Medicine, College of Bioresource and Sciences, Nihon University, Fujisawa, Kanagawa 252-0880, Japan.
Kikuya SugiuraDepartment of Advanced Pathobiology, Graduate School of Veterinary Science, Osaka Metropolitan University, Izumisano, Osaka 598-8531, Japan.
Shingo HatoyaDepartment of Advanced Pathobiology, Graduate School of Veterinary Science, Osaka Metropolitan University, Izumisano, Osaka 598-8531, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Mesenchymal stem cells (MSCs) possess immunomodulatory potential and are used for cell therapy in both human and veterinary medicine. However, donor-derived MSCs have limited proliferative activities and variations, which restrict their clinical applicability. In contrast, induced pluripotent stem cells (iPSCs) can self-renew indefinitely and differentiate into the three germ layers. By exploiting these characteristics, iPSCs can differentiate into mesenchymal stem cells (iMSCs) and potentially overcome the limitations of donor-derived MSCs. In humans, the characteristics of iMSCs have been reported to vary depending on the differentiation strategy and cell origin of iPSCs. However, no studies have investigated the differentiation strategies and cell origins of canine iPSCs (ciPSCs) in relation to iMSC generation. Methods: Canine embryonic fibroblast-derived iPSCs (CEF-iPSCs) were differentiated into iMSCs via the mesoderm or ectoderm, and their proliferative ability and the expression levels of CD34, CD44, CD45, and CD90 were assessed. We then applied the iMSC induction method via the ectoderm to other ciPSC lines, including canine dermal fibroblast-derived iPSCs (CDF-iPSCs), canine peripheral mononuclear cell-derived iPSCs (cPBMC-iPSCs), and canine urine-derived cell-derived iPSCs (cUC-iPSCs). We assessed their proliferation, marker expression, and ability to differentiate into tri-lineages and performed comparative analyses. Results: IMSCs derived from CEF-iPSCs via the ectodermal lineage showed higher proliferative ability and expressed MSC markers at a higher rate than iMSCs generated via mesodermal induction. Notably, with the exception of CDF-iPSCs, iMSCs were successfully generated from other ciPSC lines via ectodermal lineages. These iMSCs exhibited proliferative activities over passage 10, expressed MSC markers, and demonstrated the ability to differentiate into tri-lineages. iMSCs derived from cUC-iPSCs exhibited the highest expression of CD90 compared to other iMSCs. Conclusions: Highly proliferative iMSCs expressing a high rate of MSC markers can be obtained from cUC-iPSCs via ectodermal induction. Our study demonstrated that the differentiation strategy and cell origin of ciPSCs play crucial roles in the generation of iMSCs.

Indexed as

CanineInduced pluripotent stem cellMesenchymal stem cellNeural crest cellVeterinary regenerative medicine

Identifiers

PMID40511257
PMCPMC12159829

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.